Rational drug design via intrinsically disordered protein.

[1]  Gavin MacBeath,et al.  A quantitative protein interaction network for the ErbB receptors using protein microarrays , 2006, Nature.

[2]  Ernesto Estrada.  Virtual identification of essential proteins within the protein interaction network of yeast , 2005, Proteomics.

[3]  L. Vassilev,et al.  Targeting protein–protein interactions for cancer therapy , 2005, Journal of Molecular Medicine.

[4]  P. Cohen,et al.  Most nuclear systemic autoantigens are extremely disordered proteins: implications for the etiology of systemic autoimmunity , 2005, Arthritis research & therapy.

[5]  Marc S. Cortese,et al.  Coupled folding and binding with α-helix-forming molecular recognition elements , 2005 .

[6]  Michelle Arkin,et al.  Protein-protein interactions and cancer: small molecules going in for the kill. , 2005, Current opinion in chemical biology.

[7]  H. Dyson,et al.  Intrinsically unstructured proteins and their functions , 2005, Nature Reviews Molecular Cell Biology.

[8]  Zoran Obradovic,et al.  Optimizing Long Intrinsic Disorder Predictors with Protein Evolutionary Information , 2005, J. Bioinform. Comput. Biol..

[9]  Marc S. Cortese,et al.  Comparing and combining predictors of mostly disordered proteins. , 2005, Biochemistry.

[10]  Roland L. Dunbrack,et al.  Assessment of disorder predictions in CASP6 , 2005, Proteins.

[11]  P. Radivojac,et al.  PROTEINS: Structure, Function, and Bioinformatics Suppl 7:176–182 (2005) Exploiting Heterogeneous Sequence Properties Improves Prediction of Protein Disorder , 2022 .

[12]  Peter Tompa,et al.  The role of structural disorder in the function of RNA and protein chaperones , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  Carol V Robinson,et al.  Studies of the RNA degradosome-organizing domain of the Escherichia coli ribonuclease RNase E. , 2004, Journal of molecular biology.

[14]  Nikolaj Blom,et al.  Phospho.ELM: A database of experimentally verified phosphorylation sites in eukaryotic proteins , 2004, BMC Bioinformatics.

[15]  Brian W Matthews,et al.  Structural basis for the attachment of a paramyxoviral polymerase to its template. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[16]  István Simon,et al.  Preformed structural elements feature in partner recognition by intrinsically unstructured proteins. , 2004, Journal of molecular biology.

[17]  Michelle R. Arkin,et al.  Small-molecule inhibitors of protein–protein interactions: progressing towards the dream , 2004, Nature Reviews Drug Discovery.

[18]  J. S. Sodhi,et al.  Prediction and functional analysis of native disorder in proteins from the three kingdoms of life. , 2004, Journal of molecular biology.

[19]  L. Vassilev,et al.  In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2 , 2004, Science.

[20]  L. Vassilev.  Small-Molecule Antagonists of p53-MDM2 Binding: Research Tools and Potential Therapeutics , 2004, Cell cycle.

[21]  Sonia Longhi,et al.  The C-terminal domain of measles virus nucleoprotein belongs to the class of intrinsically disordered proteins that fold upon binding to their physiological partner. , 2004, Virus research.

[22]  L. Iakoucheva,et al.  The importance of intrinsic disorder for protein phosphorylation. , 2004, Nucleic acids research.

[23]  P. Chène,et al.  Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface. , 2004, Molecular cancer research : MCR.

[24]  A. Fersht,et al.  Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[25]  Leszek Rychlewski,et al.  ELM server: a new resource for investigating short functional sites in modular eukaryotic proteins , 2003, Nucleic Acids Res..

[26]  K. Tomizawa,et al.  Protein Therapy: in vivo protein transduction by polyarginine (11R) PTD and subcellular targeting delivery. , 2003, Current protein & peptide science.

[27]  A. Beavil,et al.  Handbook of Cell Signalling , 2003 .

[28]  Zoran Obradovic,et al.  Predicting intrinsic disorder from amino acid sequence , 2003, Proteins.

[29]  L. Iakoucheva,et al.  Intrinsic disorder in cell-signaling and cancer-associated proteins. , 2002, Journal of molecular biology.

[30]  P. Tompa.  Intrinsically unstructured proteins. , 2002, Trends in biochemical sciences.

[31]  L. Iakoucheva,et al.  Intrinsic Disorder and Protein Function , 2002 .

[32]  Z. Obradovic,et al.  Identification and functions of usefully disordered proteins. , 2002, Advances in protein chemistry.

[33]  B. Rost,et al.  Comparing function and structure between entire proteomes , 2001, Protein science : a publication of the Protein Society.

[34]  H. Vorum,et al.  Ca2+ Binding to α-Synuclein Regulates Ligand Binding and Oligomerization* , 2001, The Journal of Biological Chemistry.

[35]  P. Romero,et al.  Sequence complexity of disordered protein , 2001, Proteins.

[36]  V. Uversky,et al.  Why are “natively unfolded” proteins unstructured under physiologic conditions? , 2000, Proteins.

[37]  Kyou-Hoon Han,et al.  Local Structural Elements in the Mostly Unstructured Transcriptional Activation Domain of Human p53* , 2000, The Journal of Biological Chemistry.

[38]  D. Fabbro,et al.  A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines. , 2000, Journal of molecular biology.

[39]  A G Cochran,et al.  Antagonists of protein-protein interactions. , 2000, Chemistry & biology.

[40]  J. Drews.  Drug discovery: a historical perspective. , 2000, Science.

[41]  C. Brown,et al.  Intrinsic protein disorder in complete genomes. , 2000, Genome informatics. Workshop on Genome Informatics.

[42]  Kazuhito Yamamoto,et al.  BCL-2 Is Phosphorylated and Inactivated by an ASK1/Jun N-Terminal Protein Kinase Pathway Normally Activated at G2/M , 1999, Molecular and Cellular Biology.

[43]  B. Wasylyk,et al.  p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53 , 1999, Oncogene.

[44]  Obradovic,et al.  Predicting Disordered Regions from Amino Acid Sequence: Common Themes Despite Differing Structural Characterization. , 1998, Genome informatics. Workshop on Genome Informatics.

[45]  J. Hoh,et al.  Entropic exclusion by neurofilament sidearms: a mechanism for maintaining interfilament spacing. , 1997, Biochemistry.

[46]  J. Drews,et al.  Drug Development: The role of innovation in drug development , 1997, Nature Biotechnology.

[47]  David P. Lane,et al.  Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo , 1997, Current Biology.

[48]  G. Labesse,et al.  Deciphering protein sequence information through hydrophobic cluster analysis (HCA): current status and perspectives , 1997, Cellular and Molecular Life Sciences CMLS.

[49]  A. Levine,et al.  Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.

[50]  Anna Tempczyk,et al.  Crystal structures of human calcineurin and the human FKBP12–FK506–calcineurin complex , 1995, Nature.

[51]  R. Hodges,et al.  Lactam bridge stabilization of α‐helical peptides: Ring size, orientation and positional effects , 1995 .

[52]  Georg E. Schulz,et al.  Nucleotide binding proteins , 1979 .

[53]  D. Koshland,et al.  Comparison of experimental binding data and theoretical models in proteins containing subunits. , 1966, Biochemistry.